trial · primary record
CART22-65s cells
Chemotherapy Resistant Acute Lymphoblastic Leukemia
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 23 |
| Primary completion | 2036-01 |
| Primary endpoint | Assess the safety of CART22-65s in ALL subjects using the common terminology criteria of adverse events (CTCAE) v5.0. |
| Registry ID | NCT03620058 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:42:50.070Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03620058
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.